Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
RiboPGT121-LS
- Development stage
- Preclinical
- Lead developer
- BioNTech
- Modality
- mRNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Lipid-based Nanoparticles → Nanoparticles → Drug Delivery Systems
- Administration
- Intravenous, Intramuscular
01
Overview
RiboPGT121-LS is an mRNA-based therapeutic candidate developed by BioNTech for the treatment and prevention of HIV-1 infection. It consists of mRNA encoding the broadly neutralizing antibody (bNAb) PGT121, which has been modified with "LS" mutations (M428L/N434S) in the Fc region to extend its half-life via increased affinity for the neonatal Fc receptor (FcRn). The mRNA is encapsulated in lipid nanoparticles (LNPs) for delivery. Upon administration, the mRNA is translated by host cells to produce and assemble the functional PGT121-LS antibody in vivo. This approach aims to circumvent the manufacturing complexities associated with recombinant protein production while maintaining the potent viral neutralization and pharmacokinetic profile of the original antibody. Preclinical studies in non-human primates have demonstrated that intravenous administration is well-tolerated and achieves therapeutic antibody titers comparable to recombinant protein delivery.
- Other names
- mRNA-encoded bNAb PGT121-LSRibobNAb PGT121-LS
02
Targets
FCGRT (Neonatal crystallizable fragment receptor)FcγR (Low affinity immunoglobulin gamma Fc region receptor II-c)Human immunodeficiency virus 1 envelope glycoprotein 120 V3-glycan supersite (HIV-1 gp120 V3-glycan supersite)
Beyond the preview
Go deeper on RiboPGT121-LS.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on RiboPGT121-LS.